Evidence map›Paper›PMID 41739646›Full record

ArticleCell reports2026

FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages.

Xiao Lei Chen, Kevin M Tharp, Marjaana Ojalill, Duygu Ozmadenci, Antonia Boyer, Terrance J Haanen, Christine Lawson, Hyojae J Lee, Marvin Xia, Elise Tahon and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Xiao Lei ChenDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Kevin M TharpSanford Burnham Prebys Discovery Institute, Cancer Metabolism and Microenvironment Program, La Jolla, CA, USA.
Marjaana OjalillDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Duygu OzmadenciDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Antonia BoyerDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Terrance J HaanenDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Christine LawsonDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Hyojae J LeeDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Marvin XiaDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Elise TahonDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Yichi ZhangDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Cray MinorSanford Burnham Prebys Discovery Institute, Cancer Metabolism and Microenvironment Program, La Jolla, CA, USA.
Safir Ullah KhanDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Colin C AndersonDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Travis NemkovDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Michael RoseDepartment of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Monica V EstradaDepartment of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Alfredo A MolinoloDepartment of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Elias WarrenDepartment of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Patrick PenalosaDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Ramez N EskanderDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Michael T McHaleDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
Shizhen E WangDepartment of Pathology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Denise C ConnollyFox Chase Cancer Center, Cancer Signaling and Microenvironment Program, Philadelphia, PA, USA.
Kathleen M FischDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal and Fetal Medicine, University of California, San Diego, La Jolla, CA, USA.
Dwayne G StupackDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA.
David D SchlaepferDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, University of California, San Diego, La Jolla, CA, USA. Electronic address: dschlaepfer@health.ucsd.edu.

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Dissecting FAK-regulated oncogenic signaling programs in ovarian cancerR01CA247562 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D, STUPACK, DWAYNE G. · 2020 to 2024
$2.3M
Reprogramming the Tumor Microenvironment in Ovarian CancerR01CA254342 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D · 2020 to 2024
$2.1M
NCI NIH HHS R01 CA247562NCI NIH HHS R01 CA254342NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) is a lethal malignancy characterized by therapy resistance. Focal adhesion kinase (FAK) is highly expressed in HGSOC, yet its impact on tumor-immune communication remains incompletely defined. Using three syngeneic ovarian cancer models, we show that FAK inhibition (FAKi) increased macrophage CXCL13 expression and promoted peritoneal B cell infiltration. Combining FAKi with low-dose pegylated doxorubicin and anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) checkpoint blockade suppressed orthotopic ovarian tumor growth, extended survival, and induced tertiary lymphoid structures. Macrophage lineage factor GATA6 inactivation reduced CXCL13 expression, enhanced FAK-knockout tumor growth, and limited ascites B cell accumulation. Mechanistically, FAKi-treated or FAK-deficient tumor cells release exosomes enriched in omega-3 fatty acids that stimulated macrophage CXCL13 production. Exposure of macrophages to tumor-derived omega-3 lipids or eicosapentaenoic acid induced anti-tumor reprogramming and CXCL13 expression. Together, these findings reveal a tumor lipid-macrophage signaling axis activated by FAKi that supports B cell recruitment and anti-TIGIT immunotherapy.

Indexed as

Chemokine CXCL13Fatty Acids, Omega-3Focal Adhesion Kinase 1Macrophages, PeritonealOvarian NeoplasmsAnimalsCell Line, TumorDoxorubicinExosomesFemaleHumansMiceMice, Inbred C57BLChemokine CXCL13Cxcl13 protein, mouseDoxorubicinFatty Acids, Omega-3Focal Adhesion Kinase 1CP: cancerCXCL13exosomesFAKimmunotherapylipidomicsmacrophagesmicroenvironmentomega-3ovarianTIGIT

Identifiers

PMID41739646
PMCPMC13086164

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.